Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of a significant decline in short interest in August. As of August 31st, there was short interest totalling 1,290,000 shares, a decline of 20.4% from the August 15th total of 1,620,000 shares. Based on an average daily volume of 531,800 shares, the short-interest ratio is currently 2.4 days.

Brainstorm Cell Therapeutics Price Performance

BCLI traded down $0.02 on Monday, reaching $0.27. 442,645 shares of the company’s stock were exchanged, compared to its average volume of 744,446. The stock has a market cap of $18.64 million, a PE ratio of -0.83 and a beta of 0.35. Brainstorm Cell Therapeutics has a twelve month low of $0.13 and a twelve month high of $1.08. The stock’s fifty day moving average price is $0.33 and its 200-day moving average price is $0.42.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). During the same quarter last year, the business earned ($0.27) EPS. As a group, research analysts predict that Brainstorm Cell Therapeutics will post -0.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 14.33% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on BCLI. Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Thursday, July 11th. StockNews.com began coverage on shares of Brainstorm Cell Therapeutics in a research report on Sunday. They set a “hold” rating on the stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.